Jing Chen-Roetling1, Wei Song1, Hyman M Schipper1, Christopher S Regan1, Raymond F Regan2. 1. From the Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (J.C.-R., C.S.R., R.F.R.); and Lady Davis Institute, Jewish General Hospital, Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada (W.S., H.M.S.). 2. From the Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (J.C.-R., C.S.R., R.F.R.); and Lady Davis Institute, Jewish General Hospital, Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada (W.S., H.M.S.). Raymond.Regan@jefferson.edu.
Abstract
BACKGROUND AND PURPOSE: Heme oxygenase-1 (HO-1) catalyzes the rate-limiting reaction of heme breakdown and may have both antioxidant and pro-oxidant effects. In previous studies, HO-1 overexpression protected astrocytes from heme-mediated injury in vitro. In the present study, we tested the hypothesis that selective astrocyte overexpression of HO-1 improves outcome after intracerebral hemorrhage. METHODS: Male and female transgenic mice overexpressing human HO-1 driven by the GFAP promoter (GFAP.HMOX1) and wild-type controls received striatal injections of autologous blood (25 μL). Blood-brain barrier disruption was assessed by Evans blue assay and striatal cell viability by methylthiazolyldiphenyl-tetrazolium bromide assay. Neurological deficits were quantified by digital analysis of spontaneous cage activity, adhesive removal, and elevated body swing tests. RESULTS: Mortality rate for wild-type mice was 34.8% and was similar for males and females; all GFAP.HMOX1 mice survived. Striatal Evans blue leakage at 24 hours was 23.4±3.2 ng in surviving wild-type mice, compared with 10.9±1.8 ng in transgenics. Perihematomal cell viability was reduced to 61±4% of contralateral at 3 days in wild-type mice, versus 80±4% in transgenics. Focal neurological deficits were significantly reduced and spontaneous cage activity was increased in GFAP.HMOX1 mice. CONCLUSIONS: Selective HO-1 overexpression in astrocytes reduces mortality, blood-brain barrier disruption, perihematomal cell injury, and neurological deficits in an autologous blood injection intracerebral hemorrhage model. Genetic or pharmacological therapies that acutely increase astrocyte HO-1 may be beneficial after intracerebral hemorrhage.
BACKGROUND AND PURPOSE:Heme oxygenase-1 (HO-1) catalyzes the rate-limiting reaction of heme breakdown and may have both antioxidant and pro-oxidant effects. In previous studies, HO-1 overexpression protected astrocytes from heme-mediated injury in vitro. In the present study, we tested the hypothesis that selective astrocyte overexpression of HO-1 improves outcome after intracerebral hemorrhage. METHODS: Male and female transgenic mice overexpressing humanHO-1 driven by the GFAP promoter (GFAP.HMOX1) and wild-type controls received striatal injections of autologous blood (25 μL). Blood-brain barrier disruption was assessed by Evans blue assay and striatal cell viability by methylthiazolyldiphenyl-tetrazolium bromide assay. Neurological deficits were quantified by digital analysis of spontaneous cage activity, adhesive removal, and elevated body swing tests. RESULTS: Mortality rate for wild-type mice was 34.8% and was similar for males and females; all GFAP.HMOX1mice survived. Striatal Evans blue leakage at 24 hours was 23.4±3.2 ng in surviving wild-type mice, compared with 10.9±1.8 ng in transgenics. Perihematomal cell viability was reduced to 61±4% of contralateral at 3 days in wild-type mice, versus 80±4% in transgenics. Focal neurological deficits were significantly reduced and spontaneous cage activity was increased in GFAP.HMOX1mice. CONCLUSIONS: Selective HO-1 overexpression in astrocytes reduces mortality, blood-brain barrier disruption, perihematomal cell injury, and neurological deficits in an autologous blood injection intracerebral hemorrhage model. Genetic or pharmacological therapies that acutely increase astrocyte HO-1 may be beneficial after intracerebral hemorrhage.
Authors: K R Wagner; Y Hua; G M de Courten-Myers; J P Broderick; R N Nishimura; S Y Lu; B E Dwyer Journal: Cell Mol Biol (Noisy-le-grand) Date: 2000-05 Impact factor: 1.770
Authors: Nobutaka Horie; Anne-Lise Maag; Scott A Hamilton; Hideo Shichinohe; Tonya M Bliss; Gary K Steinberg Journal: J Neurosci Methods Date: 2008-06-25 Impact factor: 2.390
Authors: Rene Schmidt; Eva Tritschler; Alexander Hoetzel; Torsten Loop; Matjaz Humar; Leonie Halverscheid; Klaus K Geiger; Benedikt H J Pannen Journal: Ann Surg Date: 2007-06 Impact factor: 12.969
Authors: Lei Liu; Mary K Vollmer; Marie G Kelly; Victoria M Fernandez; Tyler G Fernandez; Hocheol Kim; Sylvain Doré Journal: Mol Neurobiol Date: 2019-09-07 Impact factor: 5.590